US Patent

US8518437 — Lipid carrier compositions with enhanced blood stability

Formulation · Assigned to Celator Pharmaceuticals Inc · Expires 2026-06-07 · 0y remaining

Vulnerability score 43/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects lipid carrier compositions, specifically liposomes, that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety.

USPTO Abstract

Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.

Drugs covered by this patent

Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.

Patent Metadata

Patent number: US8518437
Jurisdiction: US
Classification: Formulation
Expires: 2026-06-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Celator Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.